New research reveals that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who end conventional diet and exercise programs.
Published data in a prominent health publication shows that while overweight people often shed substantial amounts of their body weight while using the jabs, the mass is regained at an estimated rate of 0.8 kg per month once they quit.
"Individuals buying such medications should be cognizant of the potential of fast rebound weight gain when the medication is stopped," cautioned expert Dr. Susan Jebb.
This pace of regain means a reversion to original weight within about 18 months.
Weighing Therapies
The analysis, which looked at dozens of studies involving thousands of patients, compared the outcomes of these new drugs with other pills.
Researchers emphasize that people who lose weight through dieting typically have a slower weight regain—around 100 grams monthly—after stopping.
Explaining the Quick Rebound
Nutrition scientists suggest the way of the jabs explains the accelerated rebound.
The injections imitate a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Long-term administration of the hormone levels far above than normal may cause the system to generate a reduced amount of its own natural hormone, and could reduce sensitivity to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication leads to hunger is no longer kept in check, making overeating far more likely."
A Lifelong Issue?
Medical guidelines advise the injections for people with weight-linked health risks, accompanied by recommended lifestyle changes.
Professionals argue that, considering the significant potential of weight regain, the therapy is often life-long.
This perspective is reinforced by pharmaceutical companies, who say that the results "underscore the chronic character of excess weight," comparing it to managing diseases like high blood pressure.
Patient Accounts
Individuals who have stopped the medication report a intense return of hunger.
"It was like a trigger that goes on and you're instantly extremely hungry," described a patient.
The struggle is worsened if users have not established permanent lifestyle or habit changes during treatment.
Widespread Interest
Figures indicate that a significant number of people in the UK have used weight-loss jabs in the past year, with demand continuing to grow.
- Adoption is more common among women compared to men.
- The 40s and 50s demographic shows the greatest usage rates.
- Many access the medications through private prescriptions rather than the NHS.
Ultimately, researchers emphasize that while these medications are powerful tools for weight loss, they are not a standalone fix and long-term success likely depends on integrated lifestyle management.
